| Literature DB >> 28325266 |
Filippo Alongi1, Stefano Arcangeli2, Berardino De Bari3, Niccolò Giaj-Levra4, Alba Fiorentino1, Rosario Mazzola1, Marco Trovò5.
Abstract
Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC). The successful role option of SBRT in early NSCLC in terms of local control and toxicity profile opened the issue in the use of this approach in early stage small cell lung cancer (SCLC). Aim of this review is to discuss the current literature in the safety and efficacy of SBRT in the treatment of patients with stage I SCLC.Entities:
Keywords: Outcomes; Small cell lung cancer; Stereotactic ablative radiotherapy; Toxicity
Mesh:
Year: 2017 PMID: 28325266 DOI: 10.1016/j.critrevonc.2017.02.010
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN: 1040-8428 Impact factor: 6.312